Effect of N-acetylcystein in myocardial infarctio

Not Applicable

• Conditions: Myocardial Infarction.; Acute myocardial infarction

• Registration Number: IRCT201210118698N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Inclusion Criteria:Myocardial infarction patients who were candidate of primary PCI .

Exclusion Criteria

rescue pci;
emergency for cardiac bypass ;
cardiogenic shock;
life expactancy less than 6 months;
Age less than 18 years old;
Uncontrolled hypertension;
Thrombocytopenia;
Malformation or aneurysm;
sever chronic renal failure;
Sever liver failure;
treatment with glycoprotein IIb/IIIa inhibitors during PCI ;
sensitivity to sulfonamides ;
Major surjery;
Unsatisfactory to enter to study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL-10 biomarker of stenosis. Timepoint: after intervention. Method of measurement: Serum concentration ng/ml.;TGF-ß biomarker of stenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml.;CD40L biomarker of restenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml.;P-selectin biomarker of restenosis. Timepoint: After intervention. Method of measurement: serum concentration ng/ml.

Secondary Outcome Measures

Name	Time	Method
TIMI a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number.;MBG a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number.;MACE. Timepoint: 30-daye after intervention. Method of measurement: observation.;Added at 2014-08-03: Major Adverse cardiac events. Timepoint: Added at 2014-08-03: 30 days and 2 years. Method of measurement: Added at 2014-08-03: call to patient.